• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

    2/7/24 7:27:29 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email
    SC 13G/A 1 p24-0414sc13ga.htm BIOXCEL THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    BioXcel Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    09075P105

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 09075P10513G/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    465,381

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    465,381

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    465,381

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.55%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     

     

    CUSIP No. 09075P10513G/APage 3 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    465,381

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    465,381

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    465,381

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.55%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 09075P10513G/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    465,381

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    465,381

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    465,381

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.55%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. 09075P10513G/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    465,381

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    465,381

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    465,381

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.55%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 09075P10513G/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    465,381

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    465,381

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    465,381

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.55%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 09075P10513G/APage 7 of 10 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is BioExcel Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”) with respect to the Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), as general partner of ACP with respect to the Common Stock directly owned by ACP;
       
      (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), as managing member of ACPGP, general partner of ACP, with respect to the Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson (“Mr. Atchinson”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock  directly owned by ACP; and
       
      (v) Phillip Gross (“Mr. Gross”), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the Common Stock directly owned by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      09075P105

     

    CUSIP No. 09075P10513G/APage 8 of 10 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.                       

     

      Item 4. OWNERSHIP
        A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
          (a) Amount beneficially owned:  465,381
          (b) Percent of class:  1.55%.  The percentage set forth in this Schedule 13G/A is calculated based upon 29,929,997 shares of Common Stock outstanding as of December 31, 2023, as reported in the Company’s Registration Statement on Form S-3, filed with the Securities and Exchange Commission on January 12, 2024.
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  465,381
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition of:  465,381
               

     

    ACP has the power to dispose of and the power to vote the Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP.  ACA, as managing member of ACPGP, directs ACPGP’s operations. Neither ACPGP nor ACA directly own any Common Stock.  By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the “Act”), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.

     

     

    CUSIP No. 09075P10513G/APage 9 of 10 Pages

     

     

      B. Robert Atchinson and Phillip Gross
        (a) Amount beneficially owned:  465,381
        (b) Percent of class:  1.55%
        (c) (i) Sole power to vote or direct the vote:  0
          (ii) Shared power to vote or direct the vote:  465,381
          (iii) Sole power to dispose or direct the disposition:  0
          (iv) Shared power to dispose or direct the disposition:  465,381

     

    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the Common Stock beneficially owned by ACP.  Neither Mr. Atchinson nor Mr. Gross directly own any Common Stock.  By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 09075P10513G/APage 10 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 7, 2024

     

    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL ADVISORS, L.L.C.  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ROBERT ATCHINSON  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    PHILLIP GROSS  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

     

    Get the next $BTAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTAI

    DatePrice TargetRatingAnalyst
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    8/15/2023$40.00 → $4.00Buy → Neutral
    Mizuho
    7/17/2023Buy → Neutral
    Guggenheim
    3/10/2023$20.00 → $22.00Buy → Hold
    Jefferies
    12/1/2022$16.00Sell → Neutral
    Goldman
    7/7/2022$19.00Buy
    Mizuho
    4/6/2022$80.00Buy
    BofA Securities
    2/16/2022$88.00 → $25.00Buy
    UBS
    More analyst ratings

    $BTAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting NEW HAVEN, Conn., May 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with b

      5/12/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – The potential for artificial intelligence (AI) in healthcare is still unfolding, both for patients and providers. A recent report from Deloitte found that 71% of healthcare industry leaders expect improved profitability this year, and it comes with rising AI implementation in care. At a global level, the World Health Organization (WHO) recently launched a new AI collaboration center for healthcare through the Digital Ethics Center at Delft University of Technology in the Netherlands, while the World Economic Forum (WEF) is championing prior

      4/16/25 8:58:00 AM ET
      $AMST
      $BTAI
      $PLTR
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

      Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

      3/27/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioXcel Therapeutics Inc.

      10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      5/12/25 9:00:36 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      5/12/25 7:15:26 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by BioXcel Therapeutics Inc.

      S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)

      4/4/25 4:16:14 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

      Vincent J. O'Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company's strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O'Neill, M.D., Senior Vice

      12/11/23 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

      NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. "We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be

      7/5/22 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

      NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO). "We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "With over 25 years of commercial and industry exper

      1/19/22 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioXcel Therapeutics Inc.

      SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      9/10/24 10:47:52 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioXcel Therapeutics Inc. (Amendment)

      SC 13D/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      6/6/24 8:29:42 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BioXcel Therapeutics Inc. (Amendment)

      SC 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

      2/9/24 8:35:57 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

      Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

      4/6/22 2:18:32 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 20% to 10,158 units (SEC Form 4)

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      5/1/25 7:23:09 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by O'Neill Vincent

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      4/1/25 6:08:53 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Mehta Vimal

      4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

      4/1/25 6:08:00 PM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioXcel Therapeutics downgraded by UBS with a new price target

      UBS downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $9.00 previously

      2/21/24 8:16:51 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded BioXcel Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

      8/15/23 7:17:23 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics downgraded by Guggenheim

      Guggenheim downgraded BioXcel Therapeutics from Buy to Neutral

      7/17/23 7:16:08 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BTAI
    Financials

    Live finance-specific insights

    See more
    • BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

      Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2

      3/27/25 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

      Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's dementia Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. "Our focus continues to be the clinical development of BXCL501," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. "We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for t

      11/14/24 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

      NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2024 financial results on Thursday, November 14, 2024, before the open of the U.S. financial markets. The Company's management team will also host a conference call and webcast at 8:00 AM ET that day to discuss these results and provide a general business update. Conference Call and Webcast DetailsDate/Time:Thursday, November 14, 2024, at 8:00 AM ETParticipant Dial-In:877-407-5795 / 201-689-8722  The webcast link will be accessibl

      11/8/24 7:00:00 AM ET
      $BTAI
      Biotechnology: Pharmaceutical Preparations
      Health Care